NCT02137187 (APAF-CRT) is a Phase 3 clinical trial of AV junction ablation in Permanent Atrial Fibrillation, sponsored by Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella.

Who is sponsoring NCT02137187?

NCT02137187 is sponsored by Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella.

What drugs are being tested in NCT02137187?

Interventions in NCT02137187: AV junction ablation, CRT, Optimized drug therapy, ICD.

What condition does NCT02137187 study?

NCT02137187 studies Permanent Atrial Fibrillation.

Is NCT02137187 still recruiting?

NCT02137187 is currently status unknown. Last updated 20 January 2021.

Last reviewed 2021-01-20 · How we verify

NCT02137187: APAF-CRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Atrioventricular Junction Ablation and Biventricular Pacing for Atrial Fibrillation and Heart Failure

Status unknown Phase 3 Last updated 20 January 2021

What this trial tests

Phase 3 trial testing AV junction ablation in Permanent Atrial Fibrillation in 1,830 participants. Status unknown.

Timeline

15 October 2014

Primary endpoint
15 May 2021

31 July 2021

Quick facts

Lead sponsor	Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,830
Start date	15 October 2014
Primary completion	15 May 2021
Estimated completion	31 July 2021
Sites	1 location across Italy

Drugs / interventions tested

AV junction ablation
CRT
Optimized drug therapy — full drug profile →
ICD

Conditions studied

Permanent Atrial Fibrillation — all drugs for Permanent Atrial Fibrillation →

Sponsor

Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella — full company profile →

Who can join

18 and older, any sex, with Permanent Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is evidence of superiority of AV junction ablation strategy over pharmacological therapy only for symptoms of atrial fibrillation, but not for heart failure, hospitalization, morbidity and mortality. Hypothesis of trial is that AV junction ablation is superior to pharmacological therapy as regard hospitalization and mortality

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial.
Brignole M, Pentimalli F, Palmisano P, Landolina M, et al · · 2021 · cited 165× · PMID 34453840 · DOI 10.1093/eurheartj/ehab569
A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrial fibrillation and narrow QRS.
Brignole M, Pokushalov E, Pentimalli F, Palmisano P, et al · · 2018 · cited 119× · PMID 30165479 · DOI 10.1093/eurheartj/ehy555
New perspectives and future directions in the treatment of heart failure.
Pellicori P, Khan MJI, Graham FJ, Cleland JGF. · · 2020 · cited 32× · PMID 31327116 · DOI 10.1007/s10741-019-09829-7

Verify or expand the search:

Other Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella trials

Trials by the same sponsor.

NCT03803215 — Theophylline for Low Adenosine Syncope · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02137187 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella
Last refreshed: 20 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02137187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing